Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
OsteosarcomaPulmonary Recurrence of Osteosarcoma
Interventions
PROCEDURE

Surgical Resection

Removal of all lung nodules, including the radiated nodule, per the standard of care for osteosarcoma patients with lung metastasis.

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

Dose level 1: 8 Gy\* 3 (Total 24 Gy) Dose level 2: 18 Gy\* 3 (Total 54 Gy)

DRUG

Atezolizumab

For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle

Trial Locations (1)

30322

RECRUITING

Chilldren's Healthcare of Atlanta, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Emory University

OTHER